// App-Quantinova.ai

: Abiraterone or docetaxel in men with metastatic castration-sensitive prostate cancer: A pooled analysis of castration resistance-free survival and toxicity.

Researchers

Presenter

  • Joelle Helou

Principal Investigators

  • Charles N Catton

  • Glenn Bauman

  • Rouhi Fazelzad

  • Jacques Raphael

Medical Centers

  • University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Western University, London Regional Cancer Program, London, ON, Canada

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved